Patents Assigned to Genentech
  • Antibodies to tumor necrosis factor receptor associated factor polypeptides
    Patent number: 7754858
    Abstract: The invention concerns antibodies to new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of tumor necrosis factor (TNF) biological activities.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • Methods and compositions for detecting CDN apoptosis-modulating proteins
    Patent number: 7754418
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: Michael C. Kiefer, Philip J. Barr
  • Antibodies for inhibiting blood coagulation and methods of use thereof
    Patent number: 7749498
    Abstract: Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Jin-an Jiao, Hing C. Wong, Jinghai Wen
  • Anti-TAT188 antibodies
    Patent number: 7749504
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • Antibodies to IL-17 polypeptides and therapeutic uses thereof
    Patent number: 7749500
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood
  • Apo-2 receptor polynucleotides
    Patent number: 7749755
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Pentacyclic kinase inhibitors
    Patent number: 7749994
    Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: July 6, 2010
    Assignees: Genentech, Inc., Hoffman-LaRoche, Inc. (US Only), F. Hoffman-LaRoche, AG (EX-US)
    Inventors: Thomas E. Rawson, Brian Safina, Jennafer Dotson, Aihe Zhou, Ignacio Aliagas-Martin, Jason Halladay, Jun Liang, Matthias Rueth, Bing-Yan Zhu, Frederick Brookfield, Michael Prime, Birong Zhang, Jun M. Li
  • Apo-2 receptor polypeptides
    Patent number: 7750118
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Polypeptide variants with altered effector function
    Publication number: 20100166749
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Application
    Filed: November 12, 2009
    Publication date: July 1, 2010
    Applicant: Genentech, Inc.
    Inventor: Leonard Presta
  • ALTERED BR-3 BINDING POLYPEPTIDES
    Publication number: 20100166741
    Abstract: The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.
    Type: Application
    Filed: July 12, 2007
    Publication date: July 1, 2010
    Applicants: Genentech , Inc., Biogen Idec Ma Inc.
    Inventors: Robert F. Kelley, Amy Yijuan Shen, Dorothea Reilly, Mark S. Dennis, Germaine Fuh, Chingwei V. Lee, Christine M. Ambrose, Jeffrey S. Thompson
  • Human DR4 antibodies and uses thereof
    Patent number: 7744881
    Abstract: Human Death Receptor 4 (DR4) antibodies are provided. The human DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: June 29, 2010
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Kyung Jin Kim
  • Assays and methods using biomarkers
    Publication number: 20100158856
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: October 23, 2009
    Publication date: June 24, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS
    Publication number: 20100158898
    Abstract: The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration.
    Type: Application
    Filed: October 5, 2009
    Publication date: June 24, 2010
    Applicants: Genentech, Inc., Novartis AG
    Inventors: Jun LIU, Steven J. SHIRE
  • Isolated stra6 polypeptides
    Patent number: 7741439
    Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Diane Pennica, Victoria Smith, William I. Wood
  • ApO2 ligand/TRAIL formulations
    Patent number: 7741282
    Abstract: The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Tanya P. Lin, Zahra Shahrokh, Heather Flores, Roger Pai, Timothy C. Matthews
  • Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
    Patent number: 7741096
    Abstract: The present disclosure provides crystals of and structural coordinates of Hepatocyte growth factor activator with and without bound pseudo-substrate or inhibitor. In a specific embodiment, a crystal structure of activated HGFA complexed with a Kunitz domain inhibitor is provided. The crystals and crystal structures are useful, for example, in the design and synthesis of inhibitors of HGFA.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, Jr., Daniel K. Kirchhofer
  • Polypeptide variants
    Patent number: 7741072
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • APO-2 ligand/trail formulations
    Patent number: 7741285
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • Use of A33 antigens and JAM-IT
    Patent number: 7741056
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, Menno Van Lookeren, William I. Wood
  • Inhibitors of angiopoietin-like 4 protein, combinations, and their use
    Patent number: 7740846
    Abstract: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Napoleone Ferrara, Xiao Huan Liang